(Q36204315)

12 August 2017

1 reference

title

Potential role of prostaglandins and leukotrienes in multiple sclerosis and experimental allergic encephalomyelitis (English)

1 reference

12 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

13 October 2022

author name string

D. J. Fretland

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1603816

13 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1603816

13 October 2022

publication date

1 April 1992

1 reference

full work available at URL

12 August 2017

https://api.elsevier.com/content/article/PII:0952327892900803?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

https://api.elsevier.com/content/article/PII:0952327892900803?httpAccept=text/plain

13 October 2022

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Prostaglandins, Leukotrienes and Essential Fatty Acids

13 October 2022

published in

1 reference

12 August 2017

volume

45

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

249-257

1 reference

MS: a localized immune disease of the central nervous system

12 August 2017

cites work

3

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

MS: a CNS and systemic autoimmune disease

13 October 2022

4

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

T-cell recognition of myelin basic protein

13 October 2022

6

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Basic proteins from the acidic extract of bovine spinal cord

13 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Essential chemical requirements for induction of allergic encephalomyelitis

13 October 2022

8

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Structure and Function of Myelin Protein Genes

13 October 2022

9

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Patterns of blood-brain barrier breakdown in inflammatory demyelination

13 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Experimental allergic encephalomyelitis

13 October 2022

12

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Remitting-relapsing EAE in nonhuman primates: a valid model of multiple sclerosis

13 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Optimum conditions for inducing chronic relapsing experimental allergic encephalomyelitis in guinea pigs

13 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Chronic relapsing experimental allergic encephalomyelitis: cerebrospinal fluid cytology and a comparison with meningeal and spinal cord pathology.

13 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Endothelial cell expression of the intercellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental allergic encephalomyelitis

13 October 2022

17

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Sequence of tissue responses in the early stages of experimental allergic encephalomyelitis (EAE): immunohistochemical, light microscopic, and ultrastructural observations in the spinal cord

13 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Prostaglandin E2, leukotriene C4, and platelet-activating factor receptor sites in the brain. Binding parameters and pharmacological studies

13 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Monocyte and polymorphonuclear leukocyte toxic oxygen metabolite production in multiple sclerosis

13 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Leukotrienes B4 and C4 in MS

13 October 2022

24

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Prostaglandin levels in cerebrospinal fluid from multiple sclerosis patients in remission and relapse

13 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils

13 October 2022

26

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Prostaglandin release in multiple sclerosis: correlation with disease activity

13 October 2022

27

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Prostaglandin production in chronic progressive multiple sclerosis

13 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

In vitro study of mediators of inflammation in multiple sclerosis

13 October 2022

29

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Cerebrospinal fluid eicosanoids as an index of cerebrovascular status

13 October 2022

31

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

A longitudinal study of the prostaglandin content of central nervous system tissues from guinea pigs with acute experimental allergic encephalomyelitis (EAE).

13 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Prostaglandin and thromboxane levels in central nervous system tissues from rats during the induction and development of experimental allergic encephalomyelitis (EAE).

13 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Arachidonic and docosahexanoic acid content of bovine brain myelin: implications for the pathogenesis of multiple sclerosis

13 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Simultaneous visualization of vascular permeability change and leukocyte egress in the central nervous system during autoimmune encephalomyelitis

13 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Cytokines as inflammatory mediators

13 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Immunoregulation by leukotrienes and other lipoxygenase metabolites

13 October 2022

38

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Recombinant human interleukin-1 beta primes human polymorphonuclear leukocytes for stimulus-induced myeloperoxidase release

13 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Interferon-gamma augments hydrolysis of LTA4 to LTB4 by endothelial cells

13 October 2022

40

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

13 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Blood to brain transport of interleukin links the immune and central nervous systems

13 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis

13 October 2022

45

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

13 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Differential tumor necrosis factor alpha expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains

13 October 2022

49

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Diagnostic and therapeutic trials in multiple sclerosis: a new look. Summary of Jekyll Island workshop

13 October 2022

52

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages

13 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

The biology and clinical applications of interleukin 2

13 October 2022

57

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases

13 October 2022

58

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Cytokines in the central nervous system of mice during chronic relapsing experimental allergic encephalomyelitis

13 October 2022

60

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases

13 October 2022

61

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Complement-derived peptide mediators of inflammation

13 October 2022

63

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Rapid induction of neutrophil–endothelial adhesion by endothelial complement fixation

13 October 2022

65

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

The pathogenesis of demyelinating disease: insights from cell biology

13 October 2022

68

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Cerebrospinal fluid C9 in demyelinating disease

13 October 2022

70

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement

13 October 2022

71

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis

13 October 2022

72

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Modulation of the chemotactic properties of complement fragments C5a and C3 by the anti-inflammatory agent, SC-41930

13 October 2022

73

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Leukotriene B4 and inflammatory disease

13 October 2022

74

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Suppression of experimental autoimmune encephalomyelitis by dual cyclo-oxygenase and 5-lipoxygenase inhibition

13 October 2022

75

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Inhibition of experimental allergic encephalomyelitis by a new anti-inflammatory compound--SK&F 86002

13 October 2022

76

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Effect of the leukotriene B4 receptor antagonist, SC-41930, on experimental allergic encephalomyelitis (EAE) in the guinea pig

13 October 2022

77

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

SC-41930 inhibits neutrophil infiltration of the cavine dermis induced by 12(R)-hydroxyeicosatetraenoic acid

13 October 2022

79

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A.

13 October 2022

81

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Pharmacological comparison of active and passive experimental allergic encephalomyelitis in the rat

13 October 2022

82

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

An increase in the ratio of thromboxane A2 to prostacyclin in association with increased blood pressure in patients on cyclosporine A.

13 October 2022

84

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Induction of non-specific suppressor cells and myeloregulatory effects of an immunomodulatory azaspirane, SK&F 105685

13 October 2022

85

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Suppression of experimental allergic encephalomyelitis by 15-deoxyspergualin

13 October 2022

87

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Inhibition of chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH3

13 October 2022

88

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Suppressive effect of camostat mesilate (FOY 305) on acute experimental allergic encephalomyelitis (EAE).

13 October 2022

89

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Inhibition of experimental allergic encephalomyelitis by the alpha-glucosidase inhibitor castanospermine

13 October 2022

90

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Failure of Amantadine Hydrochloride to Alter Immune Responses in the Experimental Allergic Encephalomyelitis Model of Neuroautoimmune Disease

13 October 2022

91

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid

13 October 2022

92

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Suppression of experimental autoimmune encephalomyelitis by sulfasalazine

13 October 2022

93

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Suppression of experimental autoimmune encephalomyelitis by sulfasalazine.

13 October 2022

94

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Scavenging effect of 5-aminosalicylic acid on neutrophil-derived oxidants. Possible contribution to the mechanism of action in inflammatory bowel disease

13 October 2022

95

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Platelet-activating factor and cellular immune responses

13 October 2022

96

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Platelet-activating factor (PAF) and its relation to prostaglandins, leukotrienes and other aspects of arachidonate metabolism

13 October 2022

97

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Synergistic interaction between prostaglandins and paf-acether in experimental animals and man

13 October 2022

98

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Neuroregulatory and neuropathological actions of the ether-phospholipid platelet-activating factor

13 October 2022

99

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats

13 October 2022

101

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Platelet-activating factor antagonists do not protect against the development of experimental autoimmune encephalomyelitis

13 October 2022

103

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Response to platelet-activating factor of platelets from patients with multiple sclerosis

13 October 2022

104

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

The detection of lipocortins 1, 2 and 5 in central nervous system tissues from Lewis rats with acute experimental allergic encephalomyelitis

13 October 2022

105

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Lipocortin-1 is an endogenous inhibitor of ischemic damage in the rat brain

13 October 2022

106

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

The role of mast cells in the elicitation of experimental allergic encephalomyelitis

13 October 2022

107

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Attenuation of experimental autoimmune encephalomyelitis by Compound 48/80 in Lewis rats

13 October 2022

108

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Mast cell proteases liberate stable encephalitogenic fragments from intact myelin

13 October 2022

109

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

The effects of the anti-glucocorticoid RU 38486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat

13 October 2022

111

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis

13 October 2022

112

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells

13 October 2022

113

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Phosphosugars are potent inhibitors of central nervous system inflammation

13 October 2022

114

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Suboccipital puncture of guinea pigs.

13 October 2022

116

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Immune modifying effects of misoprostol and natural prostaglandins

13 October 2022

117

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone

13 October 2022

118

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Regulation of the immune response by prostaglandins

13 October 2022

119

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

Effects of the prostaglandin analogue misoprostol on inflammatory mediator release by human monocytes

13 October 2022

120

1 reference

https://api.crossref.org/works/10.1016/0952-3278(92)90080-3

13 October 2022

Identifiers

1 reference

12 August 2017

1 reference